Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-11-28
2009-08-25
Paras, Jr., Peter (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100
Reexamination Certificate
active
07579328
ABSTRACT:
A pro-inflammatory T cell response is specifically suppressed by the injection into a recipient of DNA encoding an autoantigen associated with autoimmune disease. The recipient may be further treating by co-vaccination with a DNA encoding a Th2 cytokine, particularly encoding IL4. In response to the vaccination, the proliferation of autoantigen-reactive T cells and the secretion of Th1 cytokines, including IL-2, IFN-γ and IL-15, are reduced.
REFERENCES:
patent: 5939400 (1999-08-01), Steinman et al.
patent: WO 86/01540 (1986-03-01), None
patent: WO 94/23737 (1994-10-01), None
patent: WO 97/45144 (1997-12-01), None
patent: WO 97 45144 (1997-12-01), None
patent: WO 97/45144 (1997-12-01), None
patent: WO 97 46253 (1997-12-01), None
patent: WO 97/46253 (1997-12-01), None
patent: WO 00/78360 (2000-12-01), None
Concalves M, A concise peer into the bqackground, initial thoughts, and practices of human gene therapy, 2005, BioEssays, vol. 27, pp. 506-517.
Parekh-Olmedo H, Gene therapy progress and prospects: targeted gene rapair, 2005, Gene Therapy, vol. 12, pp. 639-646.
Verma IM, Gene Therapy: Twenty-first century medicine, 2005, Annu. Rev. Biochem. vol. 74, pp. 711-738.
Liu M, Immunization of non-human primates with DNA vaccines, 1997, vol. 15, pp. 909-912.
Elliott E, Immune tolerance mediated by recombinant proteolipid protein prevents experimental autoimmune encephalomyelitis, J. of Neuroimmunology, 1997, vol. 79, pp. 1-11.
Karpus W, Inhibition of relapsing experimental autoimmune enchephalomyelitis in SJL mice by feeding the immunodominant PLP139-151 peptide, 1996, J. of Neuroscience Res., vol. 45, pp. 410-423.
Harrison L, The prospect of vaccination to prevent type I diabetes, 2005, Human Vaccines, vol. 1, pp. 143-150.
Ichinose et al., Recent advancement of understanding pathogenesis of type I diabetes and potential relevance to diabetic nephrothapy, 2007, Am J Nephrology, vol. 27, pp. 554-564.
Di Marzio et al., Macroangiopathay in adults and children with diabetes: from molecular mechanisms to vascular damage, 2006, Horm Metab Res., vol. 38, pp. 691-705.
Concalves M, A concise peer into the background, initial thoughts, and practices of human gene therapy, 2005, BioEssays, vol. 27, pp. 506-517.
Parekh-Olmedo H, Gene therapy progress and prospects: targeted gene repair, 2005, Gene Therapy, vol. 12, pp. 639-646.
Verma IM, Gene Therapy: Twenty-first century medicine, 2005, Annu. Rev. Biochem. vol. 74, pp. 711-738.
Yang et al., Lessons on autoimmune diabetes from animal models, 2006, Clinical Sciences, vol. 110, pp. 627-639.
Sasaki et al., Adjuvant formulations and delivery systems for DNA vaccines, 2003, Methods, vol. 31, pp. 243-254.
Editorial, Guns, genes and spleen: a coming of age for rational vaccine design, 2003, Methods, vol. 31, pp. 183-192.
Donnolly et al., 2005, J. Immunology, vol. 175, pp. 633-639.
Toyoda et al., 1998, Bioessays, vol. 20(9), pp. 750-757.
Coon et al., Jul. 1999, JCI, vol. 104(2), pp. 189-194.
Krieg et al., 1998, PNAS, vol. 95, pp. 12631-12636.
Krieg et al., 1999, J. Gene Med., vol. 1, pp. 56-63.
Krieg et al., 1998, Trends in Microbiology, vol. 6(1), pp. 23-27.
Ristori et al. (2000)Myelin Basic protein intramolecular spreading without disease progression in a patient with multiple sclerosis. J. of Neuroimmunology. 110:240-243.
Ellmerich et al. (2005) High Incidence of Spontaneous Disease in an HLA-DR15 and TCR Transgenic Multiple Sclerosis Model. J. Immunol. 174:1938-1946.
Elkman L. (2005) Voluntary Suspension of Tysabri Marketing. Letter, pp. 1-2.
Sobel et al, Neurochem Res. 19:915-921, 1994.
Klinman et al . The Journal of Immunology 158:3635-3639, 1997.
Baker et al (Gene Therapy 10:844-853, 2003.
Nowicka J et al., “Protective Effect of Naked DNA Immunization in Experimental Autoimmune Encephalitis.”,Journal of Neuroimmunology, Sep. 1, 1998, p. 102, vol. 90(1).
Chow YH et al., “Development of Th1 and Th2 Populations and the Nature of Immune Responses to Hepatitis B Virus DNA Vaccines Can Be Modulated by Codelivery of Various Cytokine Genes”,Journal of Immunology, Feb. 1, 1998, pp. 1320-1329, vol. 160(3).
Ruiz PJ et al., Suppressive Immunization with DNA Encoding a Self-Peptide Prevents Autoimmune Disease: Modulation of T Cell Costimulation,Journal of Immunology, Mar. 15, 1999, pp. 3336-3341, vol. 162(6).
Garren Hideki et al., “Combination of Gene Delivery and DNA Vaccination to Protect From and Reverse Th1 Autoiimune Disease Via Deviation to the Th2 Pathway”,Immunity, Jul. 2001, pp. 15-22, vol. 15(1).
Kolodka, Tadeusz M., et al., “Gene therapy for diabetes mellitus in rats by hepatic expression of insulin”,Proceedings of the National Academy of Sciences USA, Apr. 1995, pp. 3293-3297, vol. 92, National Academy of Science, Washington, D.C., United States.
Urbanek-Ruiz, Irene, et al., “Immunization with DNA Encoding an Immunodominant Peptide of Insulin Prevents Diabetes in NOD Mice”,Clinical Immunology, Aug. 2001, pp. 164-171, vol. 100 No. 2, Academic Press, United States.
Anderton et al., European Journal of Immunology, Apr. 1998, vol. 28:1251-1261.
Barnett et al., Journal of Neuroimmunology, vol. 64:163-173.
Bebo et al., Journal of Neuroscience Research, vol. 45:680-689.
Cohen, et al., Hosp. Practice, May 1997, pp. 169-177.
Davis, et al., Human Mol. Genetics, 1993, V.11, pp. 1847-1851.
Davis, et al., Vaccine, 1994 V. 12, No. 16, pp. 1503-1509.
Falo, et al., Nature Medicine, V . 4, No. 11, Nov. 1998, pp. 1239-1240.
Greer, et al., J. of Immunology, V. 149, Aug. 1992, pp. 783-788.
Kerlero de Rosbo, et al., J. of Autoimmunity, 1998, V. 11, pp. 287-299.
King, et al., Nature Medicine, V. 4, No. 11, Nov. 1998, pp. 1281-1286.
Krieg, et al., Trends in Microbiology, V. 6, No. 1, Jan. 1998, pp. 23-27.
Leadbetter, et al., J. of Immunology, Mar. 1998, 161, pp. 504-512.
Ledley, FD., Pharmaceutical Research, vol. 13:1595-1613.
Mor, et al., Am. Assoc. of Immunologists, 1995, V. 155, pp. 2039-2046.
Nicholson, et al., Proc. Natl. Acad. Sci., V. 94, Aug. 1997, pp. 9279-9284.
Offner, et al., J. of Immunology, 1998, V. 161, pp. 2178-2186.
Oksenberg, et al., Curr. Opinion in Immunology, 1990, V. 2, pp. 619-621.
Oksenberg, et al., Nature, V. 362, Mar. 1993, pp. 68-70.
Pardoll, et al., Immunity, V. 3, Aug. 1995, pp. 165-169.
Rawshaw et al., Immunology and Cell Biology, vol. 75:409-413.
Sato et al., Science, vol. 273-352-354.
Syrengelas, et al., Nature Medicine, V. 2(9), Sep. 1996, pp. 1038-1041.
Tang, et al., Nature, V. 356, Mar. 1992, pp. 152-154.
Tsunoda et al., Journal of Neuropathology and Experimental Neurology, vol. 57(8):758-767.
Ulmer, et al., Current Opinion in Immunology, 1996, vol. 8, pp. 531-536.
Ulmer, et al., Science, V. 259, Mar. 1993, pp. 1745-1749.
Waisman, et al., Nature Medicine, V. 2(8), Aug. 1996, pp. 899-905.
Xu, et al., Immunology, V. 84, 1995, pp. 173-176.
Diehl, Hans-Josef, et al.; “Individual exons encode the integral membrane domains of human myelin proteolipid protein”,Proc. Natl. Acad. Sci.; 1986, pp. 9807-9811, vol. 83.
Kamholz, John, et al.; “Identification of three forms of human myelin basic protein by cDNA cloning”,Proc. Natl. Acad. Sci.; 1986; pp. 4962-4966; vol. 83.
Pham-Dinh, Danielle, et al.; “Characterization and expression of the cDNA coding for the human myelin/oligodendrocyte glycoprotein”,J. Neurochemistry; 1994, pp. 2353-2356, vol. 63.
Hilton, Adrienne A., et al.; “Characterization of cDNA and genomic clones encoding human myelin oligodendrocyte glycoprotein”,J. Neurochemistry; 1995; pp. 309-318, vol. 65.
Sato, Shuzo, et al.; “cDNA cloning and amino acid sequence for human myelin-associated glycoprotein”;Biochemical and Biophysical Research Communications; Sep. 29, 1989; pp. 1473-1480; vol. 163, No. 3.
Spagnol; G., et al.; “Molecular cloning of human myelin-associated glycoprotein”,Journal of Neuroscience Research.; 1989; pp. 137-142; vol. 24.
Trotter, John L., et al.; “T cell recognition of myelin proteolipid protein and myelin proteolipid protein peptides in the peripher
Garren Hideki
Ruiz Pedro
Steinman Lawrence
Montanari David
Paras, Jr. Peter
The Board of Trustees of the Leland Stanford Junior University
Townsend and Townsend / and Crew LLP
LandOfFree
DNA vaccination for treatment of multiple sclerosis and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with DNA vaccination for treatment of multiple sclerosis and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DNA vaccination for treatment of multiple sclerosis and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4099130